Achillion Pharma starts dosing in Phase 1 HCV drug trial
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684. The trial aims to enroll around 78 healthy subjects and 40 HCV
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Radius products include BA058 Injection and BA058 Microneedle Patch. The BA058 Microneedle Patch uses 3M’s patented Microstructured Transdermal System microneedle technology to administer BA058 through the skin, as